In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

SCYNEXIS, Inc.. Trade Record

NASDAQ:SCYX SCYNEXIS, Inc. stock gains 29.17% Exit Jun 4, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart SCYX May 11, 2018, priceSeries
About SCYNEXIS, Inc.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Trade Information
Trade Type
Entry Date
May 11, 2018
Entry Price
Sell Date
Jun 4, 2018
Sell Price
Net Gain
Hold Time
15 Trading Days